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32.5% oncology, 17.5% auto-immune, 15% cardiovascular, 10% neurology/mental 
health, 5% infectious, 5% diabetes, and 15% other. Modeling techniques included 
discrete event simulation (12%), individual state-transition (15%) and most com-
monly state transition with tracking states. In most cases treatment sequencing 
was modeled to reflect clinical practice or clinical trial design. Other reasons 
included assessing where in a treatment sequence the new treatment belongs 
or evaluating the addition of more efficacious treatment options to the current 
treatment sequence. Efficacy inputs were generally based on trials that consid-
ered a single intervention and not a treatment sequence. Efficacy was commonly 
assumed to be the same regardless of line of therapy. Disease-related costs and 
utilities were mostly determined by disease status or its related events, and only 
seldomly by line of therapy. ConClusions: Capturing treatment sequences in 
economic models is important for informing reimbursement, policy and clini-
cal decisions. Key considerations for determining how to best model sequences 
include: the number of treatment options, patient heterogeneity, key outcome 
events and event risk (time-varying or constant). A key challenge to model treat-
ment sequences is the scarcity of the clinical data as clinical trials do not com-
monly study sequences.
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objeCtives: To conduct budget impact analysis of neurotrophic and neuropro-
tective drug cerebrolysin with standard therapy compared to standard therapy 
only of ischemic stroke of moderate and severe degrees of severity according to 
the Russian healthcare system. Methods: The one year budget impact analy-
sis was conducted. We used the pharmacoeconomic analysis method – budget 
impact analysis and analysis of the direct and indirect costs. For reference, 
we accepted the exchange rate was 1 EUR = 60,64 RUB. Results: Direct costs 
include the cost of pharmacotherapy cerebrolysin, the cost of medical emergen-
cies, inpatient and outpatient - polyclinic medical care, as well as the cost of 
early neurorehabilitation, and indirect costs - the loss of gross domestic product 
as a result of disability and death, payments for sick leave and disability cost. 
As a result, the overall costs of standard treatment with cerebrolysin totaled 
378 278 RUB (6238 EUR); while the cost to standard therapy was 457 981 RUB 
(7552 EUR). Reducing the direct and indirect costs was obtained in the treatment 
group of cerebrolysin, because of lower mortality and reduce days of hospital 
stay compared with the standard therapy. ConClusions: The results of budget 
impact analysis showed that the inclusion of cerebrolysin in standard therapy of 
ischemic stroke of moderate and severe degrees of severity can reduce the over-
all cost of the Russian health care system at 79 703 RUB (1314 EUR) per patient 
per year.
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objeCtives: To compare methods for extrapolating survival curves for previ-
ously-untreated patients receiving nivolumab versus ipilimumab for BRAF wild-
type advanced melanoma (AM, comprising unresectable Stage III and/or Stage IV 
metastatic melanoma). Methods: Patient-level data from 203 patients with AM 
receiving nivolumab in a phase III study (nivolumab versus dacarbazine) were used 
to estimate hazards of progression and death. Of these, 56.2% (n= 114) progressed 
and 23.2% (n= 47) died during the study period. Weibull, log-logistic and a Weibull 
mixture cure model (MCM) were fitted to extrapolate trial data for overall survival 
(OS) and progression-free survival (PFS) up to a 10 year time horizon. To estimate 
transition probabilities for subjects receiving ipilimumab, hazard ratios were cal-
culated by indirect comparison of nivolumab versus ipilimumab and applied to 
underlying survival distributions. Models were evaluated graphically, using Akaike’s 
Information Criterion (AIC) and naive comparison of the extrapolated ipilimumab 
survival functions with published long-term survival data. Results: AIC scores for 
the Weibull, log-logistic and MCM were 336.47, 335.30 and 776.20 for OS, respectively. 
The equivalent AIC scores for PFS were 511.39, 479.38 and 1421.63. The estimated 
3-year survival rate of patients receiving ipilimumab was 2.8%, 15.1% and 55.8% 
and 14.9%, 40.2% and 87.2% for patients receiving nivolumab using the Weibull, log-
logistic and MCM, respectively. This compares with published data showing approxi-
mately 21% (95% CI: 17-24%) of AM patients receiving ipilimumab (3 mg/kg) survive 
three years. Due to the short follow-up period for this study, the MCM introduced 
the greatest potential for error. ConClusions: The log-logistic model provided 
the closest approximation to real-world ipilimumab data. The choice of parametric 
model exerts a large effect on predicted effectiveness and cost-effectiveness of 
new therapies and needs justification. Different models should be considered in 
sensitivity analyses to estimate their impact on ICERs.
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bACkgRound: The health consequences attributed to cigarette smoking and sec-
ondhand smoke exposure have been studied in many countries. Nevertheless, the 
economic burden of smoking, especially focusing on secondhand smoke is rarely 
dealt with. objeCtives: To examine economic and health outcomes of secondhand 
smoking in Korea Methods: We reviewed previous studies which demonstrated the 
states (preclinical, MCI, mild, moderate, or severe AD). Patients’ rate of progres-
sion through the health states was based on a weighted average of rates among 
‘slow’ and ‘fast’ progressing patients (derived from the AD neuroimaging initia-
tive). Each state has unique utility and expenditure impacts. This lifetime horizon 
model tracks AD progression, life years, quality-adjusted life years, and expendi-
ture. ConClusions: This new framework provides a relatively simple and flexible 
way for users to simulate long-term AD and MCI health outcomes and assess the 
comparative effectiveness of strategies using a common trial endpoint.
PRM92
a coMPaRIson of dIscRete event sIMulatIon (des) veRsus MaRkov 
Models WIth a PRactIcal aPPlIcatIon to huMan-IMMunodefIcIency 
vIRus (hIv)
Gillies H
Abacus International, Bicester, UK
objeCtives: When conducting an economic evaluation, it is important to select an 
appropriate model type and provide a justification. Many analyses utilise Markov 
models but these are associated with a number of limitations. Discrete Event 
Simulation (DES) models, in which events are estimated using discrete time inter-
vals rather than regular cycles and patients are simulated individually rather than 
as a cohort, can overcome many of the Markovian limitations. The aim of this study 
was to assess the advantages and disadvantages of DES and Markov models; utilis-
ing an application to HIV. Methods: A systematic literature review was conducted 
to identify modelling approaches assessing the cost-effectiveness of HIV treatments. 
Additionally, the use of DES models within Health Technology Assessments (HTA) 
was evaluated. A de novo DES was developed in Microsoft Excel® with VBA, based 
on assumptions and data from an existing cost-effectiveness Markov model assess-
ing HIV treatments. Results: Of the HIV publications identified, 4% used a DES 
and 42% used a Markov model. Only 17% provided a discussion around their choice 
of model type. DES models have not yet been used in HTAs for HIV in the UK but 
nine were identified within other disease areas. The de novo DES and those in the 
published literature demonstrated a realistic modelling approach due to the dis-
crete timing of events and accounting for patient heterogeneity. The DES is a flex-
ible model which can accommodate future adaptations; however, it relies heavily 
on data requirements in order to maximise its potential benefit. ConClusions: 
Neither Markov models nor DES are superior; the key is to choose the most suit-
able model for the decision problem and provide a clear rationale. In the context of 
HIV, DES is likely to be a good choice of model providing sufficient data is available.
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objeCtives: We demonstrate an approach to select evidence-based preventive treat-
ment thresholds by optimizing preferred outcomes illustrated with a study on preven-
tive statin treatment based on 10-year coronary heart disease (CHD) risk predicted 
by the Framingham risk score (FRS). Methods: A Markov decision-analytic model 
was used to simulate cohorts following usual care; preventive statin treatment in 
high-risk (FRS≥ 20%) individuals (ATPIII guideline), or, alternatively, an explorative 
approach of lowering treatment threshold T from 20.0% to 0.0% with 0.5% decre-
ments. A population-based cohort (n= 11,649) was used to recalibrate the FRS and 
calculate the distribution of individuals over the low (< 0.5T%), intermediate (0.5T%-
T%), and high (≥ T%) risk category and corresponding observed CHD risks. Treatment 
complications, quality-adjusted life-years (QALYs), and Net Health Benefit (NHB) 
(willingness-to-pay of $50,000/QALY) were evaluated. Uncertainty was assessed 
through probabilistic sensitivity analysis. Furthermore, we assessed the balance 
between additional individuals treated and additional health benefits when incre-
mentally lowering the threshold. Results: Over a 30-year time horizon, QALYs in 
men ranged from 12.679 at T= 20.0% to 12.752 at T= 0.0%, with a maximum of 12.753 
at T= 1.5%. For women QALYs ranged from 13.474 at T= 20.0% to 13.587 at T= 0.0%, with 
a maximum of 13.589 at T= 1.5%. Lowering the threshold monotonically increased 
costs, whereas the incremental NHB was favorable for every T< 20%. Incrementally 
lowering the threshold and comparing outcomes to the former threshold, for men and 
women marginal health effects achieved a maximum at T= 10.0%, whereas marginal 
costs were highest at T= 1.0% for men and T= 2.5% for women. The marginal NHB was 
favorable down to T= 2.0% for men and T= 3.5% for women. ConClusions: Risk-
stratified prevention is increasingly recommended, while current intuition-based 
treatment threshold selection leaves ample room for health gain and cost-savings. 
Evidence-based selection, including estimation of long-term (marginal) health effects 
and costs, is essential, whether the goal is to maximize health outcomes or optimize 
cost-effectiveness.
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objeCtives: As interventions available in a therapeutic area increase, the relevant 
decision question in health technology assessment (HTA) expands to include iden-
tifying the optimal treatment sequences or position for a treatment in a sequence. 
This study reviewed economic models capturing treatment sequences published 
by National Institute for Health and Care Excellence (NICE). Methods: Economic 
models including a treatment sequence assessed by NICE were reviewed as these 
HTAs generally provide comprehensive detail on modeling. The rationale for 
modeling a sequence, modeling technique used, and approach to characterizing 
clinical, cost and utility impacts were evaluated. Results: Forty models were 
identified that considered treatment sequences in the following therapeutic areas: 
